Evidence map›Paper›PMID 26242919›Full record

ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2015

Toll-like receptor 2 activators modulate oral tolerance in mice.

M C Tunis, B Dawod, K R Carson, L L Veinotte, J S Marshall

Open access · hybridAbstract read
In one paragraph

Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Gut-associated IgANature communications · 2019
    Article
  8. Article
  9. Review
  10. Toll-like receptor 2 activators modulate oral tolerance in mice.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

M C TunisDepartment of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
B DawodDalhousie Inflammation Group, Dalhousie University, Halifax, NS, Canada.
K R CarsonDepartment of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
L L VeinotteDepartment of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
J S MarshallDepartment of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
Dalhousie University · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

backgroundToll-like receptor 2 (TLR2) is a widely expressed pattern recognition receptor critical for innate immunity. TLR2 is also a key regulator of mucosal immunity implicated in the development of allergic disease. TLR2 activators are found in many common foods, but the role of TLR2 in oral tolerance and allergic sensitization to foods is not well understood.

objectiveThe purpose of this study was to evaluate the impacts of TLR2 expression and TLR2 activation on oral tolerance to food antigens in a murine model.

methodsMice were fed ovalbumin (OVA) or peanut butter with or without the addition of low doses of TLR2 activators Pam3 CSK4 or FSL-1. Oral tolerance was assessed by analysing antibody responses after a systemic antigen challenge. OVA-specific Tregs were assessed in the Peyer's patches, mesenteric lymph nodes, and spleen in wild-type and TLR2(-/-) mice. Low-dose Pam3 CSK4 was also tested as an oral adjuvant.

resultsOral tolerance was successfully induced in both wild-type and TLR2(-/-) recipient mice, with an associated regulatory T-cell response. Oral TLR2 activation, with low-dose Pam3 CSK4 or FSL-1, during oral antigen exposure was found to alter oral tolerance and was associated with the development of substantial IgE and IgA responses to foods upon systemic challenge. Low-dose oral Pam3 CSK4 treatment also selectively enhanced antigen-specific IgA responses to oral antigen exposure. CONCLUSIONS AND CLINICAL RELEVANCE: TLR2 is not necessary for oral tolerance induction, but oral TLR2 activation modulates humoral IgE and IgA responses during tolerance development. Low-dose Pam3 CSK4 is also an effective oral adjuvant that selectively enhances IgA production. These observations are pertinent to the optimization of oral allergen immunotherapy and oral vaccine development.

Indexed as

Immune ToleranceAdjuvants, ImmunologicAllergensAnimalsDiglyceridesDisease Models, AnimalFoodFood HypersensitivityImmunity, HumoralImmunoglobulin ALipopeptidesMiceMice, KnockoutOligopeptidesOvalbuminT-Lymphocytes, RegulatoryAdjuvants, ImmunologicAllergensDiglyceridesFSL-1 lipoprotein, syntheticImmunoglobulin ALipopeptidesOligopeptidesOvalbuminPam(3)CSK(4) peptideToll-Like Receptor 2AllergyIgAIgEmurineoral toleranceovalbuminpeanutTLR2Treg

Identifiers

PMID26242919
PMCPMC5019435
OpenAlexW2106305158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.